YME1L1: A Potential Drug Target and Biomarker (G10730)

Target Name: YME1L1

NCBI ID: G10730

YME1L1: A Potential Drug Target and Biomarker

YME1L1 (Y-myeloid derived factor 1-like) is a protein that is expressed in various tissues of the human body, including the brain, spleen, and peripheral blood. It is a member of the myeloid derived factor (MDF) family, which includes MDF1, MDF2, and MDF3, which are involved in the regulation of cellular processes such as inflammation, apoptosis, and fibrosis. YME1L1 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, it has become an attractive target for drug development.

Diseases associated with YME1L1

YME1L1 has been associated with the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

1. Cancer

YME1L1 has been shown to be involved in the development and progression of various types of cancer, including breast, ovarian, and prostate cancer. It has been shown to promote the growth and survival of cancer cells, and it has also been shown to play a role in the development of resistance to chemotherapy in cancer cells.

2. Neurodegenerative diseases

YME1L1 has been shown to be involved in the development and progression of various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. It has been shown to contribute to the development of neurodegeneration by promoting the production of toxic oxygen species, which can damage cellular components and contribute to the development of neurodegeneration.

3. Autoimmune disorders

YME1L1 has been associated with the development and progression of various autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. It has been shown to contribute to the development of autoimmune disorders by promoting the production of antibodies that can cause damage to cellular components and contribute to the development of autoimmune disorders.

Targeting YME1L1

Despite the potential benefits of targeting YME1L1, several challenges must be overcome before it can be used as a drug target. One of the main challenges is the lack of understanding of the underlying molecular mechanisms that regulate YME1L1. While several studies have identified potential targets for YME1L1, further research is needed to determine the full extent of its involvement in various diseases and to develop effective strategies for targeting it.

Another challenge is the development of YME1L1-targeting drugs that are safe and effective. Currently, there are no approved drugs that specifically target YME1L1. Researchers are working to develop new drugs that can be used to treat diseases associated with YME1L1, but these efforts are still in the early stages.

Conclusion

In conclusion, YME1L1 is a protein that has been associated with the development and progression of various diseases. While further research is needed to fully understand its role in these diseases and to develop effective strategies for targeting it, its potential as a drug target is a promising area of research. If successful, YME1L1 could provide new treatments for a variety of diseases and have a significant impact on the health and well-being of individuals.

Protein Name: YME1 Like 1 ATPase

Functions: ATP-dependent metalloprotease that catalyzes the degradation of folded and unfolded proteins with a suitable degron sequence in the mitochondrial intermembrane region (PubMed:26923599, PubMed:27786171). Plays an important role in regulating mitochondrial morphology and function by cleaving OPA1 at position S2, giving rise to a form of OPA1 that promotes maintenance of normal mitochondrial structure and mitochondrial protein metabolism (PubMed:18076378, PubMed:26923599, PubMed:27495975). Ensures cell proliferation, maintains normal cristae morphology and complex I respiration activity, promotes antiapoptotic activity and protects mitochondria from the accumulation of oxidatively damaged membrane proteins (PubMed:22262461). Required for normal, constitutive degradation of PRELID1 (PubMed:27495975). Catalyzes the degradation of OMA1 in response to membrane depolarization (PubMed:26923599). Required to control the accumulation of nonassembled respiratory chain subunits (NDUFB6, OX4 and ND1) (PubMed:22262461)

More Common Targets